Pacira BioSciences (NASDAQ: PCRX) Downgraded Amid Viatris Acquisition News

• Pacira BioSciences (NASDAQ: PCRX) was downgraded by Needham from Buy to Hold following news of its acquisition by Viatris.
• Viatris is set to acquire Pacira for $36.50 per share, valuing the company at approximately $1.65 billion, with the deal expected to close by late 2026.
• Despite a significant 44% stock rally, options market activity indicates a bearish sentiment for Pacira shares.

Pacira BioSciences (NASDAQ: PCRX) faces a significant stock downgrade from Needham, shifting its rating from Buy to Hold. This announcement coincided with shares trading at $36.27. Pacira BioSciences, known for developing innovative pain medicines including non-opioid treatments like EXPAREL and ZILRETTA, is the target of an acquisition. The downgrade reflects the impending deal where Viatris, a global medicines company, has agreed to acquire Pacira.

Viatris has put forth an attractive acquisition offer of $36.50 per share in cash, which values Pacira’s equity at approximately $1.65 billion. Both companies anticipate the merger and acquisition deal to finalize by the end of 2026. This strategic acquisition will significantly bolster Viatris’s portfolio by integrating Pacira’s valuable patent-protected pain medicines, a move highlighted by The Wall Street Journal.

Following the acquisition announcement, Pacira shares experienced a substantial rally, rising 44% to $36.30 on Oct. 8. At this price, the stock trades $0.20 below the cash offer, indicating a potential arbitrage opportunity. This price gap is typical and reflects the inherent risk that shareholders only receive the full offer price upon the successful closure of the deal.

Despite the recent stock rally, options trading activity for Pacira reveals a distinctly bearish sentiment, as noted by Schaeffers Research. Trading volume surged to 2,702 contracts, an extraordinary 166.1 times the usual intraday level. Notably, negative-delta activity significantly surpassed positive-delta activity, indicating that many traders are positioning for a potential decline. Negative-delta options typically increase in value when the underlying stock price falls.

For the 12 months ending June 30, 2026, Pacira reported robust financial performance, with approximately $746 million in revenue and $177 million in adjusted EBITDA. Adjusted EBITDA is a crucial measure of operating earnings that excludes specific non-recurring or non-cash costs. Currently, Pacira shares are trading at $36.31, marking an impressive gain of $11.11, or 44.07%, on a substantial trading volume of 22.74 million shares.